Cite
Phase 1/2 study of orteronel (TAK-700), an investigational 17,20-lyase inhibitor, with docetaxel-prednisone in metastatic castration-resistant prostate cancer.
MLA
Petrylak, Daniel, et al. “Phase 1/2 Study of Orteronel (TAK-700), an Investigational 17,20-Lyase Inhibitor, with Docetaxel-Prednisone in Metastatic Castration-Resistant Prostate Cancer.” Investigational New Drugs, vol. 33, no. 2, Apr. 2015, pp. 397–408. EBSCOhost, https://doi.org/10.1007/s10637-014-0199-x.
APA
Petrylak, D., Gandhi, J., Clark, W., Heath, E., Lin, J., Oh, W., Agus, D., Carthon, B., Moran, S., Kong, N., Suri, A., Bargfrede, M., & Liu, G. (2015). Phase 1/2 study of orteronel (TAK-700), an investigational 17,20-lyase inhibitor, with docetaxel-prednisone in metastatic castration-resistant prostate cancer. Investigational New Drugs, 33(2), 397–408. https://doi.org/10.1007/s10637-014-0199-x
Chicago
Petrylak, Daniel, Jitendra Gandhi, William Clark, Elisabeth Heath, Jianqing Lin, William Oh, David Agus, et al. 2015. “Phase 1/2 Study of Orteronel (TAK-700), an Investigational 17,20-Lyase Inhibitor, with Docetaxel-Prednisone in Metastatic Castration-Resistant Prostate Cancer.” Investigational New Drugs 33 (2): 397–408. doi:10.1007/s10637-014-0199-x.